BETHESDA, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN; www.regenerx.com) today closed its previously announced private placement. The company sold 5,305,557 shares of common stock at $1.80 per share for aggregate gross proceeds of $9.55 million. Participants in the financing included several new institutional investors as well as existing investors, and affiliates of Sigma-Tau Group, the company’s largest stockholder. In addition, warrants to purchase 2,122,222 shares of common stock were issued to the investors. The warrants have an exercise price of $2.75 per share. Piper Jaffray & Co. acted as sole placement agent for the transaction.
